ヒト成長ホルモン（HGH）の世界市場 - 成長、動向、予測（2019年〜2024年）
Human Growth Hormone (HGH) Market - Growth, Trends, and Forecast (2019 - 2024)
|発行||Mordor Intelligence LLP||商品コード||659350|
|出版日||ページ情報||英文 110 Pages
|ヒト成長ホルモン（HGH）の世界市場 - 成長、動向、予測（2019年〜2024年） Human Growth Hormone (HGH) Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日: 2019年03月01日||ページ情報: 英文 110 Pages||
The global human growth hormone market is expected to register a CAGR of 6.8% during the forecast period (2014 - 2024). The human growth hormone, also somatotropin, is a peptide hormone that helps to stimulate growth, cell regeneration, and cell reproduction. The increase in applications of growth hormone and the awareness about the effects of growth hormone in the treatment of short stature are major factors propelling the growth of this market. Most of the companies are investing in R&D for developing a growth hormone that has fewer side effects and will be long-acting hormonal therapy. Technical developments in the recombinant human growth hormone are also expected to boost the growth of the human growth hormone market over the forecast period.
The human growth hormone market report covers the revenue generated through the sales of various innovator and generic formulations of human growth hormone available in the global market. The estimates provided in the report covers the consumption of human growth hormones for all the major applications like growth hormone deficiency, Turner syndrome, and idiopathic short stature, among others.
By Application, Turner Syndrome Segment is Expected to Register Steady Growth.
Turner syndrome is a rare chromosomal disorder that affects females, characterized by the partial or complete loss of one of the X chromosomes. The symptoms of Turner syndrome include a wide neck and a low or indistinct hairline, tendency to develop high blood pressure, minor eye problems, drooping of the eyelids, and under-active thyroid gland. The age of diagnosis has been decreasing with better awareness of Turner syndrome in the medical community, which, in turn, is driving the studied market. Since it is associated with many complications related to heart, hearing loss, autoimmune disorders, mental health issues, infertility, and pregnancy complications, the demand for treatment involving growth hormones is increasing.
The United States accounted for the largest market share. The dominance of this country can be attributed to factors, such as high healthcare expenditure, the high prevalence of target diseases, and the availability of reimbursements. In the United States, approximately one in 4,000 to 10,000 children suffer from growth hormone deficiency and approximately 50,000 adults have growth hormone deficiency, with about 6,000 new adult patients diagnosed every year. Recombinant growth hormone has been widely available for prescription use in the United States since 1985. It is used for growth hormone deficiency (GHD), Turner's syndrome, chronic renal insufficiency, small for gestational age or intrauterine growth retardation, Prader-Willi syndrome, continued height deficit at puberty, and cachexia, or AIDS wasting.
The Asia-Pacific region is anticipated to witness the fastest growth during the forecast period as the demand for growth hormone has been rising in the emerging countries for the past few years.
The human growth hormone market is consolidated and highly competitive with a few market players controlling a significant share of the market. Furthermore, there are several active partnerships for the development of more efficacious and long-acting subtypes of human growth hormones.
Novo Nordisk is a global healthcare company which develops, manufactures, markets and distributes pharmaceuticals in 180+ countries worldwide. The firm primarily focuses on the development and marketing of biopharmaceuticals, Novo Nordisk has been a leader in the diabetes care segment for more than 90 years. The company has been a market leader in the HGH market for nearly four decades. Novo Nordisk's growth hormone Norditropin® controls more than 35% market share. Despite the patent expiry of Norditropin® in late 2017, the company had maintained its market share; this can be primarily attributed to the presence of proprietary HGH injector. Furthermore, the firm is looking forward to expanding its presence in the HGH market by introducing a long-acting HGH product Somapacitan (NN8640) which is in phase III development. If approved somapacitan is likely to drive further market expansion owing to its once per week administration requirement.
Pfizer manages its commercial operations through two distinct business segments Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH segment focuses on developing, manufacturing and commercializing novel, value-creating medicines, and vaccines while EH segment includes the legacy brands that have lost or will soon lose market exclusivity in both emerging and developed markets. Pfizer's HGH product Genotropin comes under rare disease division in IH segment. In the year 2017, Genotropin contributed to revenue of USD 532 million, which is about 24% of the revenues of the Rare Disease division. In the year 2016, somatrogon (hGH-CTP) a prospective long-acting HGH drug failed to achieve a satisfactory result in its ongoing phase III trial in adult patients. HGH-CTP was being jointly developed by Pfizer and Opko Health, Inc and was previously forecasted as a blockbuster product.